Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy

Santiago Aparo, Sanjay Goel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Colorectal Cancer is the second most common cancer in incidence and mortality in the United States. In spite of current screening strategies 1 out of 5 patients still presents with metastatic disease. During the last 10-15 years there has been significant increase in the availability of chemotherapy options for this disease. The recent introduction of molecular markers to the treatment algorithm allows oncologists to tailor treatments for each particular patient. In the following article we give an overview of the landmark publications that led to our current standards and we give our view on particular situations in which the available evidence is not so helpful in making therapeutic decisions.

Original languageEnglish (US)
Pages (from-to)47-58
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume83
Issue number1
DOIs
StatePublished - Jul 2012

Fingerprint

Colonic Neoplasms
Drug Therapy
Publications
Colorectal Neoplasms
Decision Making
Therapeutics
Mortality
Incidence
Neoplasms
Oncologists

Keywords

  • Colorectal neoplasms
  • Neoplasm metastasis
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. / Aparo, Santiago; Goel, Sanjay.

In: Critical Reviews in Oncology/Hematology, Vol. 83, No. 1, 07.2012, p. 47-58.

Research output: Contribution to journalArticle

@article{09c554fc80974f62aea5fef13728c8d8,
title = "Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy",
abstract = "Colorectal Cancer is the second most common cancer in incidence and mortality in the United States. In spite of current screening strategies 1 out of 5 patients still presents with metastatic disease. During the last 10-15 years there has been significant increase in the availability of chemotherapy options for this disease. The recent introduction of molecular markers to the treatment algorithm allows oncologists to tailor treatments for each particular patient. In the following article we give an overview of the landmark publications that led to our current standards and we give our view on particular situations in which the available evidence is not so helpful in making therapeutic decisions.",
keywords = "Colorectal neoplasms, Neoplasm metastasis, Therapy",
author = "Santiago Aparo and Sanjay Goel",
year = "2012",
month = "7",
doi = "10.1016/j.critrevonc.2011.08.006",
language = "English (US)",
volume = "83",
pages = "47--58",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy

AU - Aparo, Santiago

AU - Goel, Sanjay

PY - 2012/7

Y1 - 2012/7

N2 - Colorectal Cancer is the second most common cancer in incidence and mortality in the United States. In spite of current screening strategies 1 out of 5 patients still presents with metastatic disease. During the last 10-15 years there has been significant increase in the availability of chemotherapy options for this disease. The recent introduction of molecular markers to the treatment algorithm allows oncologists to tailor treatments for each particular patient. In the following article we give an overview of the landmark publications that led to our current standards and we give our view on particular situations in which the available evidence is not so helpful in making therapeutic decisions.

AB - Colorectal Cancer is the second most common cancer in incidence and mortality in the United States. In spite of current screening strategies 1 out of 5 patients still presents with metastatic disease. During the last 10-15 years there has been significant increase in the availability of chemotherapy options for this disease. The recent introduction of molecular markers to the treatment algorithm allows oncologists to tailor treatments for each particular patient. In the following article we give an overview of the landmark publications that led to our current standards and we give our view on particular situations in which the available evidence is not so helpful in making therapeutic decisions.

KW - Colorectal neoplasms

KW - Neoplasm metastasis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84862132933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862132933&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.08.006

DO - 10.1016/j.critrevonc.2011.08.006

M3 - Article

C2 - 21944740

AN - SCOPUS:84862132933

VL - 83

SP - 47

EP - 58

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -